PDS Biotechnology

PDS Biotechnology Corporation is a biopharmaceutical company based in North Brunswick, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. Founded in 2005, the company is dedicated to both early and late-stage cancer treatments, addressing a range of conditions including cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. Its product portfolio includes PDS0101, which targets HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a series of immunotherapy products designed for non-viral cancers. PDS Biotechnology utilizes its proprietary Versamune platform technology to activate and direct the human immune system, enabling it to effectively combat cancer cells.